I am honor to join @NarjustDumaMD and @ASCO @ConquerCancerFd to fund a YIA for Latinas in oncology conquer.org/WWCCGIFT @SandraSwainMD @EdithPerezMD @ASCOPres Please help us reach the goal! @HemOncWomenDocs

I wouldn't say that was my big takeaway of this paper or trial. The takeaway I got was there is a giant overall survival benefit for our youngest breast cancer patients to ovarian function suppression over tamoxifen. Sure, there are some low risk patients, where Tam alone is fine, but the majority of super young breast cancer patients present at later stage. If you’re going to give chemo then do not give tamoxifen alone, this needs to be more widely accepted in the community, as it’s been 15 years and the uptake is still too low. Too many oncologists do not give the youngest patients ovarian suppression, as they don't like dealing with how unpopular it is with patients, and difficult it is for patients. Yes it is hard, but it saves lives and it’s our duty to our patients to work with them on side effect management and not just abandon so easily when things get tough, as this is likely our most effective weapon in premenopausal ER breast cancer. We are failing our very young breast cancer patients who have the highest mortality from breast cancer when we do not strongly recommend this and then HELP patients with their side effects so they can stay compliant. This often take a lot of time and extra visits, but it really is so important. #Breastcancer #SOFT #TEXT

Powerful and poignant #asco2026 President’s Address by Eric Small: “The Science and Practice of Translation: Improving Cancer Outcomes Worldwide” @asco connection.asco.org/do/2026-…

#asco26: 1) if patients with 4-9 ln are reluctant to get chemo get prosigna; 2) please enroll pts to ofset. Seems ofs is all we need in low genomic premen; 3) denosumab can be spaced out; 4) geda doublet in pik3m should be considered but watch tox; 5) no 1st line serd for now

The #ASCO26 learning continues! Excited to join an outstanding faculty at #BestofASCO in 🌴☀️ Puerto Rico 🇵🇷 on June 13-14 Looking forward to great discussions, collaboration, and bringing the latest oncology advances to our community. @TotalHealthConf

Amazing 🤩 Congratulations Dr. Meza! 🎊🎉🎉

Love working at a place where people work hard, care, and know how to have fun along the way. Great #MiamiNights at #ASCO26 with our formidable @SylvesterCancer MedOnc Chair, @GlopesMd.

Wow- 🤯 I thought summarizing one #ASCO26 presentation with character limits was a challenge. @VKaklamani with a pretty good attempt to summarize all of breast into one tweet 😂 👏 🤩

What % of patients with HER2 eBC and residual disease are eligible for T-DXd according to the DB-05 criteria? 👉48% 👉the majority of patients (lower risk) remain eligible for T-DM1 👉T-DM1-only eligible patients experienced favorable real-world outcomes, despite having RD

15-year SOFT/TEXT update confirms what many of us already sensed in clinic: Not every premenopausal HR breast cancer needs endocrine escalation. But the youngest, highest-risk patients absolutely do. 🎯 🔹 Exemestane OFS continued to reduce distant recurrence vs tamoxifen OFS 🔹 Biggest absolute benefit seen in: • Age <35 • Grade 3 disease • HER2-negative tumors • Prior chemotherapy cohorts In women <35 years with HER2-negative disease: 15-year OS: ➡️ 82.5% with exemestane OFS ➡️ 68.1% with tamoxifen alone That is not a marginal difference. The real message from SOFT/TEXT in 2026: Risk-adapted endocrine therapy matters more than ever. 📈 #ASCO26 #bcsm #OncoTwitter @OncoAlert @myesmo @esmo_open @ASCO

The most trusted voice in cancer care @ASCOPost It is an honor for me to be appointed as the Senior Deputy Editor of @ASCOPost The voice of @ASCO ! Grateful to the very talented editorial board, leadership of Dr. Jim Armitage EIC, @caraglynn01 and Angela Cochran!

sometimes just giving patients a choice between what kind of chemo and letting them know this is better than none at all is more important that what type of regimen. This trial supports patient centric decisions

@ErikaHamilton9 beautifully presents additional efficacy and safety from HER2CLIMB05, at median follow up of 23 months mPFS was prolonged by 9 month. In HR- mPFS 12.6 mo improved to 24.9 mos, in HR , mPFS improved from 18.1 mo to 25 mo, those with and without baseline brains mets still derived benefit, and denovo and recurrent disease also still derived benefit. No new safety signals. @OncoAlert @SCRIOncology @SarahCannonDocs

These are really clinically relevant and practice changing data on how to optimize #denosumab use in patients with bone metastases: induction with 4 monthly administrations then every 3 months #ASCO26 @ASCO @OncoAlert @valeguarneri

#ASCO26 Great dinner with Women in Thoracic Oncology. Grateful to share ideas, mentorship, and friendship with such an inspiring group of leaders. @ASCO is not only about science and innovation, but also about lifting each other up and building community. #WomenInOncology #LungCancer #SheforShe

#ASCO26 | SERENA-6 Early switch to camizestrant CDK4/6i at the emergence of an ESR1 mutation also improved PFS2 versus continuing AI CDK4/6i. PFS2: 25.7 vs 19.1 months✅️ HR 0.63, p=0.0037 The strategy is reasonable: intervene with ctDNA before waiting for radiologic progression. But there is a design issue: if crossover to camizestrant at radiologic progression had been mandatory, we could have understood the true value of early switching at molecular relapse much more clearly. Looking forward to the discussion.

This excellent #asco26 ed session on Time to Trial Activation featuring @FDAOncology @NCIDirector @KimrynRathmell & @Dee_Anna_Smith is available around the paywall - scroll down in this link: (and watch opening ceremony and @ASCO Voices talks as well!) asco.org/annual-meeting/prog…

My #ASCO26 #FitCheck: spent Day 4 PM & Day 5 AM streaming sessions in my PJs from my hotel room while catching up on clinical work. I'm happy to have phenomenal colleagues who help cover for small acute issues but in the last 24 hrs I've had 8 plans due. 😅☢️🛠️⚡️🩻#ASCOFashion

#ASCO26 I never imagined that in the middle of my career I’d be reporting on cancer research advances and helping make them understandable for the lay public—in both English and Spanish. Grateful for the opportunity. @Lung_Cancers @sylvestercancer #CancerResearch #MedTwitter

I've waited all #ASCO26 to finally spend time with Dr @NarjustFlorezMD and now it's TIME. 🤜⚡️🤛

As #asco26 comes to a close, I think the highlight for me was connecting w/3 of my prior @ConquerCancerFd @asco IDEA mentees: Nico from Romania, Yanin from Mexico, & Anyur from Kazakhstan. All 3 have become amazing oncology leaders & are improving cancer care globally. So proud!